{"id":11920,"date":"2025-06-17T05:32:37","date_gmt":"2025-06-17T03:32:37","guid":{"rendered":"https:\/\/valintermed.com\/?p=11920"},"modified":"2025-06-17T05:32:37","modified_gmt":"2025-06-17T03:32:37","slug":"sindrom-li-fraumeni","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/syndrome-or-fraumeni\/","title":{"rendered":"Li-Fraumeni syndrome"},"content":{"rendered":"
<\/div>\n

Li-Fraumeni syndrome is a rare hereditary disease characterized by an increased risk of developing multiple malignant neoplasms at an early age. The basis of the pathology is a mutation of the TP53 gene, which plays a key role in the regulation of the cell cycle and apoptosis. The clinical picture of the disease is characterized by the development of various types of cancer, such as soft tissue and bone sarcomas, brain tumors, adenocarcinoma of the mammary gland and adrenal glands, as well as other oncological diseases that occur at a young age. The syndrome was first described in 1969 by American scientists Frederick Li and Joseph Fraumeni.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n